omiganan
Peptideexperimental
Clinical trial activity
18 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
16
Phase 3
6
Phase 4
0
Earliest trial started Sep 1, 2000 (NCT00027248)
Timeline
Indications
Studied for
Mechanism of action
- Cell membraneDISRUPTING AGENT
Cell membrane disrupting agent
Chemistry & pharmacology
Loading structure…
SMILES
CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(N)=O- Mol. weight
- 1779.18 g/mol
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1615933 ↗
Also known as
- cls001
- mbi 226
- mbi 226
- omiganan
- omiganan
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03688971 | Phase 2 | Oct 31, 2018 | Cutanea Life Sciences, Inc. |
| NCT03091426 | Phase 2 | Mar 8, 2017 | Cutanea Life Sciences, Inc. |
| NCT03071679 | Phase 1 | Feb 6, 2017 | Cutanea Life Sciences, Inc. |
| NCT02849262 | Phase 2 | Jul 1, 2016 | Cutanea Life Sciences, Inc., Leiden University |
| NCT02596074 | Phase 2 | Nov 1, 2015 | Cutanea Life Sciences, Inc. |
| NCT02547441 | Phase 3 | Oct 1, 2015 | Cutanea Life Sciences, Inc. |
| NCT02571998 | Phase 2 | Oct 1, 2015 | Cutanea Life Sciences, Inc. |
| NCT02576860 | Phase 3 | Oct 1, 2015 | Cutanea Life Sciences, Inc. |
| NCT02576847 | Phase 3 | Sep 1, 2015 | Cutanea Life Sciences, Inc. |
| NCT02456480 | Phase 2 | May 1, 2015 | Cutanea Life Sciences, Inc. |
| NCT02066545 | Phase 2 | Apr 1, 2014 | Cutanea Life Sciences, Inc. |
| NCT02028286 | Phase 1 | Jan 1, 2014 | Cutanea Life Sciences, Inc. |
| NCT01784133 | Phase 2 | Mar 1, 2013 | Cutanea Life Sciences, Inc. |
| NCT00608959 | Phase 3 | May 1, 2008 | Mallinckrodt |
| NCT00231153 | Phase 3 | Aug 1, 2005 | Mallinckrodt |
| NCT00211497 | Phase 2 | Jan 1, 2003 | BioWest Therapeutics Inc |
| NCT00211523 | Phase 2 | Oct 1, 2000 | BioWest Therapeutics Inc |
| NCT00027248 | Phase 3 | Sep 1, 2000 | BioWest Therapeutics Inc |
Showing 18 of 18 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cutanea Life Sciences, Inc. | For profit | 13 | 13 | 3 | 2013 |
| BioWest Therapeutics Inc | For profit | 3 | 3 | 2 | 2000 |
| Mallinckrodt | For profit | 2 | 2 | 1 | 2005 |
| Leiden University | Academic/Hospital | 1 | 0 | 1 | 2016 |
4 organizations
Page 1 / 1